Lydia Visser
PhD
My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.
Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach
Published in: PLoS ONE
Access to document
10.1371/journal.pone.0193098
document
Forty percent of patients with diffuse large B-cell lymphoma (DLBCL) show resistant disease to standard chemotherapy (CHOP) in combination with the anti-CD20 monoclonal antibody rituximab (R). Although many new anti-cancer drugs were developed in the last years, it is unclear which of these drugs can be safely combined to improve standard therapy without antagonizing anti-CD20 efficacy. In this study, we aimed to identify rituximab compatible drug-target combinations for DLBCL. For this, we collected gene expression profiles of 1,804 DLBCL patient samples. Subsequently, we performed a guilt-by-association analysis with...
Mathilde R. W. de Jong, Lydia Visser, Gerwin Huls, Arjan Diepstra, Marcel van Vugt, Emanuele Ammatuna, Rozemarijn S. van Rijn, Edo Vellenga, Anke van den Berg, Rudolf S. N. Fehrmann, Tom van Meerten
Erratum: Lydia Visser et al. Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma
Published in: International Journal of Molecular Sciences
Access to document
10.3390/ijms19010304
document
The authors regret to have made a mistake in publishing this paper [1] with an incorrect author list […]
MicroRNA High Throughput Loss-of-Function Screening Reveals an Oncogenic Role for miR-21-5p in Hodgkin Lymphoma
Published in: Cellular physiology and biochemistry
Access to document
10.1159/000492850
document
Background/Aims: Classical Hodgkin lymphoma (cHL) is among the most frequent lymphoma subtypes. The tumor cells originate from crippled germinal center (GC)-B cells that escaped from apoptosis. MicroRNAs (miRNAs) play important roles in B-cell maturation and aberrant expression of miRNAs contributes to the pathogenesis of cHL. Our aim was to identify oncogenic miRNAs relevant for growth of cHL using a high-throughput screening approach. Methods: A lentiviral pool of 63 miRNA inhibition constructs was used to identify miRNAs essential to cell growth in three cHL cell lines in duplicate. As...
Ye Yuan, Fubiao Niu, Ilja M. Nolte, Jasper Koerts, Debora de Jong, Bea Rutgers, Jan Osinga, Maria Azkanaz, Martijn Terpstra, Leonid Bystrykh, Arjan Diepstra, Lydia Visser, Agnieszka Dzikiewicz-Krawczyk, Klaas Kok, Joost Kluiver, Anke van den Berg
ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma
Published in: Leukemia
Access to document
10.1038/leu.2017.94
document
A Dzikiewicz-Krawczyk, K Kok, I Slezak-Prochazka, J-L Robertus, J Bruining, M M Tayari, B Rutgers, D de Jong, J Koerts, A Seitz, Jun Li, B Tillema, J. Guikema, I M Nolte, A Diepstra, Lydia Visser, J Kluiver, A. van den Berg
Lymphadenopathy driven by TCR-Vγ8Vδ1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome
Published in: Blood
Access to document
10.1182/bloodadvances.2017006411
document
FAS-dependent apoptosis in Vδ1 T cells makes the latter possible culprits for the lymphadenopathy observed in patients with FAS mutations.Rapamycin and methylprednisolone resistance should prompt clinicians to look for Vδ1 T cell proliferation in ALPS-FAS patients.
Stefano Vavassori, Jacob D Galson, Johannes Trück, Anke van den Berg, Rienk Y J Tamminga, Aude Magerus-Chatinet, Olivier Pellé, Ulrike Camenisch Gross, Ewerton Marques Maggio, Seraina Prader, Lennart Opitz, Ursina Nüesch, Andrea Mauracher, Benjamin Volkmer, Oliver Speer, Luzia Suda, Benno Röthlisberger, Dieter Robert Zimmermann, Rouven Müller, Arjan DiepstraLydia Visser, Eugenia Haralambieva, Bénédicte Neven, Frédéric Rieux-Laucat, Jana Pachlopnik Schmid